Could a dengue vaccine be safe for autoimmune patients? new trial aims to find out
NCT ID NCT07087912
First seen Jun 27, 2026 · Last updated Jul 21, 2026 · Updated 2 times
Summary
This study tests whether the Butantan-Dengue vaccine is safe and works well in people aged 12–59 with autoimmune rheumatic diseases (like rheumatoid arthritis or lupus) who are stable on low or no immune-suppressing drugs. Participants receive one vaccine dose and are monitored for side effects and immune response for a year. Results will be compared to healthy volunteers to see if the vaccine triggers similar protection.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANTIPHOSPHOLIPID SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hospital das Clínicas da Faculdade de Medicina da USP
RECRUITINGSão Paulo, São Paulo, 01246-903, Brazil
-
Rheumatology Division, Faculdade de Medicina da USP
RECRUITINGSão Paulo, São Paulo, Brazil
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can skin biopsies unlock new treatments for scleroderma?
- Could a gut microbiome transplant ease axial spondyloarthritis?
- Could a skin patch ease stomach pain in scleroderma?
- Could a painless microneedle pad ease Raynaud's in scleroderma?
- Could a simple blood test flag heart risk in rheumatoid arthritis?
- Learning to Self-Care: a new approach to ease RA stiffness?